REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)

REKOVELLE® PEN S.C. Injection 12μg/36μg/72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06545877

Enrollment

571

Registered

2024-08-09

Start date

2022-09-16

Completion date

2026-02-28

Last updated

2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.

Exclusion criteria

* No

Design outcomes

Primary

Measure	Time frame	Description
Adverse Events	From initiation of the administration, in case of embryo transfer is not performed, until 1 week after oocyte collection, and in case embryo transfer is performed, 6 weeks after embryo transfer	Frequency of Adverse Events

Countries

Japan

Contacts

STUDY_DIRECTORGlobal Clinical Compliance

Ferring Pharmaceuticals

Outcome results